NO20006451L - Inhibitorer av transkripsjonsfaktor NF-kB - Google Patents

Inhibitorer av transkripsjonsfaktor NF-kB

Info

Publication number
NO20006451L
NO20006451L NO20006451A NO20006451A NO20006451L NO 20006451 L NO20006451 L NO 20006451L NO 20006451 A NO20006451 A NO 20006451A NO 20006451 A NO20006451 A NO 20006451A NO 20006451 L NO20006451 L NO 20006451L
Authority
NO
Norway
Prior art keywords
present
disease
transcription factor
inhibitors
activation
Prior art date
Application number
NO20006451A
Other languages
English (en)
Norwegian (no)
Other versions
NO20006451D0 (no
Inventor
James Francis Callahan
Marie C Chabot-Fletcher
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20006451D0 publication Critical patent/NO20006451D0/no
Publication of NO20006451L publication Critical patent/NO20006451L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20006451A 1998-06-19 2000-12-18 Inhibitorer av transkripsjonsfaktor NF-kB NO20006451L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8982798P 1998-06-19 1998-06-19
PCT/US1999/013652 WO1999065449A2 (en) 1998-06-19 1999-06-18 INHIBITORS OF TRANSCRIPTION FACTOR NF-λB

Publications (2)

Publication Number Publication Date
NO20006451D0 NO20006451D0 (no) 2000-12-18
NO20006451L true NO20006451L (no) 2000-12-18

Family

ID=22219773

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006451A NO20006451L (no) 1998-06-19 2000-12-18 Inhibitorer av transkripsjonsfaktor NF-kB

Country Status (21)

Country Link
US (3) US6492425B1 (cs)
EP (1) EP1085848B1 (cs)
JP (1) JP2002518307A (cs)
KR (1) KR20010052991A (cs)
CN (1) CN1311629A (cs)
AR (1) AR019692A1 (cs)
AT (1) ATE383769T1 (cs)
AU (1) AU4690099A (cs)
BR (1) BR9911152A (cs)
CA (1) CA2335294A1 (cs)
CO (1) CO5021213A1 (cs)
CZ (1) CZ20004761A3 (cs)
DE (1) DE69937997T2 (cs)
ES (1) ES2299251T3 (cs)
HU (1) HUP0102782A3 (cs)
IL (1) IL140328A0 (cs)
NO (1) NO20006451L (cs)
PL (1) PL348969A1 (cs)
TR (1) TR200003781T2 (cs)
WO (1) WO1999065449A2 (cs)
ZA (1) ZA200007447B (cs)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0951551B9 (en) 1996-12-23 2012-12-26 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
ATE517916T1 (de) 1998-05-14 2011-08-15 Immunex Corp Verfahren zur hemmung der wirkung der osteoklasten
GB9930616D0 (en) * 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
EP1134221A1 (en) * 2000-03-15 2001-09-19 Aventis Pharma Deutschland GmbH Substituted beta-carbolines as lkB kinase inhibitors
FR2813315B1 (fr) 2000-08-23 2002-10-18 Genfit S A Procede d'identification de substances utiles pour le traitement de l'inflammation mettant en oeuvre l'element de reponse du recepteur ror du gene ikbalpha
ATE553758T1 (de) * 2000-12-18 2012-05-15 Inst Med Molecular Design Inc Hemmer für die produktion und freisetzung entzündlicher zytokine
EA021242B9 (ru) 2001-06-26 2015-11-30 Эмджен Фримонт Инк. Антитела к остеопротегерин лиганду (опгл)
JP4599501B2 (ja) * 2001-11-07 2010-12-15 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 多発性骨髄腫および他の癌の処置におけるＩκＢのインヒビターとしてのカルボリン誘導体
US7119120B2 (en) 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
WO2003103648A1 (ja) * 2002-06-05 2003-12-18 株式会社医薬分子設計研究所 糖尿病治療薬
AU2003242131A1 (en) * 2002-06-05 2003-12-22 Institute Of Medicinal Molecular Design, Inc. Immunity-related protein kinase inhibitors
TW200402291A (en) * 2002-06-06 2004-02-16 Inst Med Molecular Design Inc Antiallergic
CN1658855B (zh) * 2002-06-06 2010-04-28 株式会社医药分子设计研究所 O-取代羟基芳基衍生物
TW200410675A (en) * 2002-06-10 2004-07-01 Inst Med Molecular Design Inc An NF-κB activation inhibitor
JPWO2003103655A1 (ja) * 2002-06-10 2005-10-06 株式会社医薬分子設計研究所 癌治療剤
EA011707B1 (ru) * 2002-06-11 2009-04-28 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Лекарственное средство для лечения нейродегенеративных заболеваний
US7324455B2 (en) 2003-03-14 2008-01-29 International Business Machines Corporation Transfer of error-analysis and statistical data in a fibre channel input/output system
WO2004098510A2 (en) * 2003-04-30 2004-11-18 Beth Israel Deaconess Medical Center Cystic fibrosis therapy
US20050004164A1 (en) * 2003-04-30 2005-01-06 Caggiano Thomas J. 2-Cyanopropanoic acid amide and ester derivatives and methods of their use
US20050256132A1 (en) * 2003-04-30 2005-11-17 Wyeth Use of ER selective NF-kB inhibitors for the treatment of sepsis
US7981915B2 (en) * 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
CN102793692A (zh) * 2003-07-23 2012-11-28 幸讬制药公司 用于发炎与免疫相关用途的化合物
US7425580B2 (en) 2004-05-19 2008-09-16 Wyeth (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
US20080207673A1 (en) * 2005-05-04 2008-08-28 Michel Xilinas Method for Treating Cancer, Coronary, Inflammatory and Macular Disease, Combining the Modulation of Zinc-and/or Copper Dependent Proteins
CN100418532C (zh) * 2005-06-17 2008-09-17 吕志民 治疗多种疾病的NF-κB化合物抑制剂
US7671058B2 (en) 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
AU2008314979A1 (en) 2007-10-23 2009-04-30 Institute Of Medicinal Molecular Design, Inc. Inhibitor of PAI-1 production
CN101918017B (zh) 2007-10-25 2013-07-31 植物药学公司 Phy906用于治疗炎性肠病和/或肠易激综合征的用途
US8609730B2 (en) * 2008-01-08 2013-12-17 The Trustees Of The University Of Pennsylvania Rel inhibitors and methods of use thereof
US20090264514A1 (en) * 2008-04-18 2009-10-22 The Research Foundation Of State University Of New York SPHINGOMYELIN SYNTHASE 2 (SMS2) DEFICIENCY ATTENUATES NFkB ACTIVATION, A POTENTIAL ANTI-ATHEROGENIC PROPERTY
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
EP3323813B1 (en) * 2010-12-22 2020-08-26 The Trustees of Columbia University in the City of New York Histone acetyltransferase modulators and uses thereof
TWI492920B (zh) * 2012-04-18 2015-07-21 Nat Defense Medical Ct 水楊酸苯胺衍生小分子之醫藥組合物及其製備與醫藥用途
WO2014113467A1 (en) * 2013-01-15 2014-07-24 Board Of Regents, The University Of Texas System Stat3 inhibitor
WO2015027120A1 (en) * 2013-08-21 2015-02-26 Jiang Jean X Compositions and methods for targeting connexin hemichannels
BR112016022879A2 (pt) 2014-03-31 2017-10-10 Univ Columbia ativadores de histona acetiltransferase e usos dos mesmos
EP3967312A1 (en) 2014-09-12 2022-03-16 UNION therapeutics A/S Antibacterial use of halogenated salicylanilides
CN105797154B (zh) * 2014-12-31 2020-03-10 中国科学院上海生命科学研究院 软骨干细胞的分离及其应用
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
WO2017122209A2 (en) * 2016-01-12 2017-07-20 Yeda Research And Development Co. Ltd. NF-kappaB INHIBITORS
JP7098527B2 (ja) 2016-02-26 2022-07-11 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム コネキシン（Ｃｘ）４３ヘミチャネル結合抗体及びその使用
GB201604484D0 (en) * 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
KR20190138647A (ko) * 2017-03-21 2019-12-13 노바리드 파마 인코포레이티드 포스포다이에스테라제 저해 및 관련 장애를 위한 치료제
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
BR112022009457A2 (pt) * 2019-11-18 2022-08-16 Univ California Inibidores duplos de receptor androgênico/akr1c3

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1079177A (en) * 1963-06-11 1967-08-16 Stecker Internat S P A Improvements in pesticide composition for destroying internal worm parasites in animals
GB1079178A (en) * 1966-07-27 1967-08-16 Stecker Internat S P A Improvements in pesticide compositions for destroying internal worm parasites in animals
US4742083A (en) * 1983-08-24 1988-05-03 Lever Brothers Company Method of relieving pain and inflammatory conditions employing substituted salicylamides
US4803279A (en) 1985-05-23 1989-02-07 Smithkline Beckman Corporation 1.4-dihydro-4-pyridyl-substituted imidazo (2,1-b) thiazoles and the corresponding thiazines.
DK0544812T3 (da) * 1990-08-21 1995-08-21 Upjohn Co Bisphosphonsyrederivater som anti-arthritiske midler
JPH06508029A (ja) * 1991-05-17 1994-09-14 カイロン　コーポレイション ＮＦ−↓ｋＢ転写活性化物質のインヒビター及びその使用
US5466715A (en) * 1991-12-31 1995-11-14 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
DE4200534A1 (de) * 1992-01-11 1993-07-15 Henkel Kgaa Neue n-benzyl-4-aminophenole und deren verwendung als entwicklerkomponente in oxidationshaarfaerbemitteln
WO1994028887A1 (en) * 1993-06-15 1994-12-22 The Australian National University Synergistic anthelmintic compositions
CA2298824A1 (en) * 1997-08-06 1999-02-18 Smithkline Beecham Corporation Macrophage scavenger receptor antagonists for use in the treatment of cardiovascular diseases

Also Published As

Publication number Publication date
AR019692A1 (es) 2002-03-13
CZ20004761A3 (cs) 2001-08-15
DE69937997T2 (de) 2009-02-19
PL348969A1 (en) 2002-06-17
HUP0102782A2 (hu) 2001-12-28
CN1311629A (zh) 2001-09-05
CO5021213A1 (es) 2001-03-27
ATE383769T1 (de) 2008-02-15
US20030092771A1 (en) 2003-05-15
NO20006451D0 (no) 2000-12-18
WO1999065449A2 (en) 1999-12-23
US6492425B1 (en) 2002-12-10
EP1085848A4 (en) 2004-09-08
CA2335294A1 (en) 1999-12-23
KR20010052991A (ko) 2001-06-25
WO1999065449A3 (en) 2000-03-30
DE69937997D1 (cs) 2008-03-06
BR9911152A (pt) 2001-03-06
TR200003781T2 (tr) 2001-07-23
AU4690099A (en) 2000-01-05
US20060035979A1 (en) 2006-02-16
JP2002518307A (ja) 2002-06-25
ES2299251T3 (es) 2008-05-16
EP1085848A2 (en) 2001-03-28
EP1085848B1 (en) 2008-01-16
IL140328A0 (en) 2002-02-10
ZA200007447B (en) 2002-02-13
WO1999065449A8 (en) 2001-03-08
HUP0102782A3 (en) 2002-12-28

Similar Documents

Publication Publication Date Title
NO20006451L (no) Inhibitorer av transkripsjonsfaktor NF-kB
NO995543L (no) Monoestere fra probukol for behandling av kardiovaskulær og inflammatorisk sykdom
CY1108301T1 (el) Συνθεση περιλαμβανουσα αναστολεα αποακετυλασης ιστονης εμφανιζουσα διφασικη απελευθερωση
MXPA06000326A (es) Novedosos compuestos y composiciones que contienen esteroles y/o estanoles e inhibidores de biosintesis de colesterol, y su uso en el tratamiento o prevencion de una variedad de enfermedades y condiciones.
PL351125A1 (en) Derivatives of 4,5-diaryl-3(2)-furanone as inhibitors of cykoxygenease-2
WO2004045579A3 (en) Pharmaceutical compositions and dosage forms of thalidomide
FI945556A0 (fi) Tulehdustenvastaiset 3-aryyli-2-isoksatsoliinijohdannaiset
NO20006452L (no) Inhibitorer av transkripsjonsfaktor NF-kB
ATE234270T1 (de) Cathecoldiether als selektive pde iv hemmungsmittel
PT1049703E (pt) Aldeido do acido n-¬2-(5-benziloxicarbonilamino-6-oxo-2-(4-fluorofenil)-1,6-di-hidro-1-pirimidinil)acetoxil|-l-aspartico como inibidor da enzima de conversao da interleucina-1beta in vivo
DK1509232T3 (da) Kombination af en NMDA-antagonist og acetylcholin-esterase inhibitorer til behandling af Alzheimers sygdom
JO2216B1 (en) 5 chloro-3 (4-methane sulfonyl phenyl) -6-methyl- (2.3)
NO20045234L (no) 2,6-kinolinyl- og 2,6-naftylderivater, fremgangsmate for fremstilling av disse, og anvendelse av disse som VLA-4-inhibitorer
WO1999009000A3 (en) Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis
WO2003106450A8 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
ATE438618T1 (de) Inhibitoren von humanem adam-10
MY133512A (en) Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors
BR0008437A (pt) Inibidores esteróides de sulfatase e métodos parafabricação e uso dos mesmos
NO20053341L (no) Hindring og behandling av Alzheimers sykdom.
GB0113663D0 (en) Use of organic compounds
GR3027598T3 (en) Benzisothiazoles derivatives as inhibitors of 5-lipoxygenase biosynthesis
DE602005023874D1 (de) Octahydropyrroloä2, 3, cüpyridinderivative und pharmazeutische verwendung damit
WO2003026569A3 (en) Composition and method for the treatment of hypercholesterolemia and hyperlipidemia in mammals
Bootz Friedrich Bootz1
DE502004007517D1 (de) Anti-apoptotisch wirksame apatamere

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application